

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**Palopegteriparatide for treating chronic hypoparathyroidism ID6380**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees have highlighted the following equalities issues:

1. Post-surgical hypoparathyroidism is more common in women than men since women are more likely to have thyroidectomies as a result of increased risk of thyroid disease.
2. Issues with learning disabilities, communication difficulties and language may impair access to treatment.
3. Pregnancy may prevent patients from accessing treatment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

NICE considers appraisal technologies within their marketing authorisation for the whole population. Stakeholders will have an opportunity to submit evidence on equalities issues. As part of the technology appraisal, the committee will consider the impact of recommendations on people with protected characteristics. However, please note:

1. Issues related to differences in prevalence or incidence of a disease or a reduced life expectancy for one particular protected group cannot be addressed in a technology appraisal.

2. The committee must follow the processes and methods set out in the NICE health technology evaluation manual and are unable to divert from these methods and processes for individual evaluations or they will risk introducing further inequalities.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The background has been amended to include information about hypoparathyroidism being more common in women than men.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** Emily Crowe.....

**Date:** ...13/09/2024.